Gilva Therapeutics Collaborates with National Taiwan University to Publish First-Generation HDAC6 Inhibitors for ADPKD in the Journal of Medicinal Chemistry

Gilva Therapeutics announced that its collaborative research with National Taiwan University has been published in the prestigious Journal of Medicinal Chemistry. The study focuses on the design and development of first-generation selective histone deacetylase 6 (HDAC6) inhibitors and their therapeutic potential in autosomal dominant polycystic kidney disease (ADPKD). The findings demonstrate promising activity in disease models, supporting the potential of HDAC6 inhibition as a novel therapeutic approach. This publication highlights Gilva Therapeutics’strength in mechanism-driven small molecule drug discovery and further validates HDAC6 as a key therapeutic target for ADPKD. The company will continue advancing its pipeline toward clinical development.

🔗 Publication link:
https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5c03139?ref=article_openPDF